Annals of Oncology· @Annals_Oncology · X·· 23 hours agoScore70
Body
📢 #ESMO26 concomitant paper - Pembrolizumab plus chemotherapy for HR+/HER2− PD-L1‒positive advanced breast cancer: final analysis of the phase 3 KEYNOTE-B49 Study.
🔗https://tinyurl.com/3xrc9ycw
@hoperugo
174 views · 1 like · 1 repost · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Annals of Oncology · x.com